Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.48 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3777128 | 0.99 | SMN1; SMN2 (0.60) | SMN1; SMN2GAAALOX12ALDH1A1LMNA | |
| SCHEMBL3772241 | 0.98 | SMN1; SMN2 (0.61) | SMN1; SMN2GAAALOX12ALDH1A1LMNA | |
| SCHEMBL3763252 | 0.91 | SMN1; SMN2 (0.50) | SMN1; SMN2GAAALOX12ALDH1A1LMNA | |
| SCHEMBL3768291 | 0.90 | ALDH1A1 (0.50) | SMN1; SMN2GAAALOX12ALDH1A1LMNA | |
| SCHEMBL3770030 | 0.89 | LMNA (0.59) | SMN1; SMN2GAAALDH1A1LMNATSHR | |
| SCHEMBL3767940 | 0.89 | SMN1; SMN2 (0.50) | SMN1; SMN2GAAALOX12ALDH1A1LMNA | |
| SCHEMBL3762804 | 0.88 | LMNA (0.61) | SMN1; SMN2GAAALDH1A1LMNATSHR | |
| SCHEMBL3769384 | 0.87 | LMNA (0.59) | SMN1; SMN2GAAALDH1A1LMNATSHR | |
| SCHEMBL3774214 | 0.86 | TSHR (0.56) | ALDH1A1TSHRKMT2AMEN1SLC18A3 | |
| SCHEMBL14452912 | 0.86 | TSHR (0.71) | SMN1; SMN2ALDH1A1LMNATSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| WO-2007016496-A2 | DIPIPERAZINYL KETONES AND RELATED ANALOGUES | NEUROGEN CORPORATION (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | HRH4, HRH3, HRH1 | SMN1; SMN2 4282/4885GAA 2143/4885ALOX12 4106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.